GSK - GlaxoSmithKline plc
| Previous Close | 39.61 |
| Open | 40.42 |
| Bid | 40.60 x 4000 |
| Ask | 40.90 x 1000 |
| Day's Range | 40.36 - 40.90 |
| 52 Week Range | 34.52 - 42.36 |
| Volume | 4,203,748 |
| Avg. Volume | 2,371,034 |
| Market Cap | 99.18B |
| Beta (3Y Monthly) | 0.56 |
| PE Ratio (TTM) | 46.23 |
| EPS (TTM) | 0.88 |
| Earnings Date | Feb 1, 2017 - Feb 6, 2017 |
| Forward Dividend & Yield | 1.98 (4.99%) |
| Ex-Dividend Date | 2018-08-09 |
| 1y Target Est | 44.30 |
Market Realist•2 days agoA Performance Overview of JNJ’s Beauty and OTC Businesses
Johnson & Johnson’s (JNJ) beauty business generated revenue of $1.1 billion in the third quarter compared to $1.0 billion in the third quarter of 2017, reflecting a ~4.4% YoY rise.
- Motley Fool•3 days ago
Better Buy: GlaxoSmithKline plc vs. Eli Lilly
Which stock is a better bet in an uncertain market?
- GlobeNewswire•4 days ago
NeuroMetrix Reports Q3 2018 Financial Results
WALTHAM, Mass., Oct. 17, 2018 -- NeuroMetrix, Inc. (Nasdaq: NURO), today reported financial and business highlights for the quarter ended September 30, 2018. The Company.
- Yahoo Finance•6 days ago
Trump administration: Drug makers should disclose prices in TV ads
just after drug companies announced they will be disclosing prices of drugs advertised on TV via a website, the Trump administration proposes a rule to require medicare and medicaid drugs to disclose price in TV ads.
Market Realist•9 days agoA Financial Overview of Bausch Health in October
Bausch Health’s (BHC) net revenues declined from $4.3 billion in the first half of 2017 to $4.1 billion in the first half of this year, reflecting an ~5.0% YoY (year-over-year) decline. In the second quarter, Bausch Health generated net revenues of $2.1 billion compared to $2.2 billion in the second quarter of 2017.
Market Realist•9 days agoHow Analysts View Bausch Health in October
In the second quarter, Bausch Health (BHC) reported net income and diluted EPS of -$873.0 million and -$2.49, respectively, compared to -$38.0 million and -$0.11 in the second quarter of 2017. In the first half, Bausch Health generated net income and diluted EPS of -$3.45 million and -$9.84, respectively, compared to $590.0 million and $1.68 in the first half of 2017.
- Market Realist•10 days ago
Analysts’ Estimates and Ratings for Novartis in October
Novartis’s (NVS) revenue is mainly driven by the strong performance of its Innovative Medicines segment, while Sandoz and Alcon also contribute to the company’s overall growth.
- Market Realist•11 days ago
A Closer Look at Novartis’s Innovative Medicines Segment
Novartis’s (NVS) Innovative Medicines segment includes prescription products from two business units: Novartis Pharmaceuticals and Novartis Oncology.
- Market Realist•11 days ago
How Novartis’s Businesses Have Been Performing
Novartis’s (NVS) business is separated into three segments: Innovative Medicines, the prescription medicines business Sandoz, the generics business Alcon, the eye care business
- Market Realist•12 days ago
A Look at Novartis’s Valuation on October 9
Novartis AG (NVS) reported EPS of $1.29 on revenue of $13.2 billion in the second quarter, reporting a 7% YoY (year-over-year) rise in revenue compared to $12.2 billion in the second quarter of 2017.
- American City Business Journals•13 days ago
Meet the $172.5 million biotech IPO from the U.K. with big plans to grow in the Bay Area
Orchard Rx Ltd., a London-based gene therapy company targeting "bubble boy" disease and other rare genetic conditions, wants to raise $172.5 million through an initial public offering that in part will bankroll a key Bay Area expansion. Orchard, whose shareholders include drug giant GlaxoSmithKline plc (NYSE: GSK), is the latest biotech company to take advantage of Wall Street's open cash window. It filed its IPO plans Thursday, less than two months after raising $148 million in an oversubscribed Series C round.
- Zacks•16 days ago
Merck Reports Positive Efficacy Data from Phase III HIV Study
Merck (MRK) reports positive data from the phase III DRIVE-AHEAD study, evaluating Delstrigo in treatment-naive adults with HIV-1 infection.
- Zacks•16 days ago
Gilead Announces Positive Data From Ongoing Biktarvy Study
Gilead (GILD) reports positive data from an ongoing late stage study on HIV regimen, Biktarvy at 96 weeks.
Market Realist•16 days agoAnalyzing Seattle Genetics’ Key Collaborations
Seattle Genetics (SGEN) is focused on maximizing Adcetris’ market reach. Currently, the product is sold in 71 countries. Adcetris was approved in Japan for treating frontline Hodgkin lymphoma. Seattle Genetics has a global collaboration with Takeda Pharmaceutical (TKPYY) to develop and commercialize Adcetris. While Seattle Genetics retains rights for the drug in the United States and Canada, Takeda has the rights for the drug in the rest of the world. Takeda pays Seattle Genetics a royalty.
- Zacks•17 days ago
J&J's Phase III Data Shows Switch to its HIV Drug Beneficial
Data from the 96-week long phase III EMERALD study shows that switching to J&J's (JNJ) Symtuza maintains high virologic suppression.
- Market Realist•17 days ago
GlaxoSmithKline ADR’s Performance and Revenues in Q3 2018
GlaxoSmithKline (GSK) segregates its business portfolio into three business segments—Pharmaceuticals, Vaccines, and Consumer Healthcare. As a British multinational company, GlaxoSmithKline reports its revenues in pounds sterling. The chart below compares GlaxoSmithKline’s EPS and revenues since the first quarter of 2017, as well as its estimates for the third quarter.
- The Wall Street Journal•18 days ago
[$$] Boston Pharma Adds to War Chest in Pacts With Novartis, GlaxoSmithKline
Boston Pharmaceuticals Inc., a startup backed with a $600 million funding commitment from a single investor, is bulking up its portfolio of potential medications. PLC to add to its portfolio, securing three anti-infective programs from Novartis and five products from GSK, including drugs that could treat acne and irritable bowel syndrome.
- Market Realist•18 days ago
Mergers and Acquisitions in the Pharmaceuticals Sector in Q3 2018
The US Pharmaceutical sector comprises drug manufacturers, drug marketers, and biotechnology companies. The chart below lists the recent mergers and acquisitions in the pharmaceuticals sector.
- InvestorPlace•18 days ago
6 of the Best Dividend Stocks Outside the U.S.
In this day and age, dividend investors looking for high-dividend stocks shouldn’t limit themselves to U.S. companies only. Some of the best dividend stocks over time have been foreign issuers. And that’s still the case at the moment.
- Motley Fool•18 days ago
Why Dynavax Technologies Corporation Stock Struggled in September
Dynavax's shares kept losing ground last month, but a turnaround could be close at hand.
- Reuters•19 days ago
GSK resumes some doctor payments, backtracking on blanket ban
GlaxoSmithKline (GSK.L), which five years ago stopped paying doctors for promoting its drugs, said on Tuesday it would allow such payments once again in limited circumstances. Drugmakers have long used so-called key opinion leaders to promote the benefits of their products to other prescribing physicians and the decision to abandon this strategy was questioned by a number of analysts. GSK's new updated policy on working with healthcare professionals will now permit payments to global experts who speak about the science behind novel new medicines.
- Reuters•19 days ago
GSK resumes some doctor payments, backtracking on blanket ban
GlaxoSmithKline, which five years ago stopped paying doctors for promoting its drugs, said on Tuesday it would allow such payments once again in limited circumstances. Drugmakers have long used so-called key opinion leaders to promote the benefits of their products to other prescribing physicians and the decision to abandon this strategy was questioned by a number of analysts. GSK's new updated policy on working with healthcare professionals will now permit payments to global experts who speak about the science behind novel new medicines.
- Market Realist•19 days ago
A Look at GlaxoSmithKline’s Consumer Healthcare Business
GlaxoSmithKline’s (GSK) Consumer Healthcare segment includes the consumer healthcare portfolio including oral health products, wellness products, nutrition, and skin health products. The consumer healthcare segment reported revenues of ~1.8 billion pounds during the second quarter of 2018, a 3% increase in operating revenues.
- Market Realist•19 days ago
How GlaxoSmithKline’s Vaccines Business Has Performed Recently
GlaxoSmithKline’s (GSK) Vaccines segment includes influenza vaccines, meningitis vaccines, shingles vaccines, and established vaccines. The vaccines segment reported revenues of ~1.3 billion pounds during the second quarter of 2018, a 13% increase in YoY revenues. The growth includes a 16% increase in operating revenues offset by a 3% negative impact of foreign exchange during the quarter.
